Healthcare Logistics Service Firm Owens & Minor To Buy Home-Based Care Equipment Firm For $1.4B, Sees Better Than Expected Q2 Earnings
Healthcare Logistics Service Firm Owens & Minor To Buy Home-Based Care Equipment Firm For $1.4B, Sees Better Than Expected Q2 Earnings
On Tuesday, Owens & Minor Inc. (NYSE:OMI) agreed to acquire Rotech Healthcare Holdings, Inc., a privately held home-based care business headquartered in Orlando, Florida, for $1.36 billion in cash.
週二，歐文斯和美諾公司（紐約證券交易所代碼：OMI）同意以13.6億美元現金收購總部位於佛羅里達州奧蘭多的私人家庭護理企業Rotech Healthcare Holdings, Inc.。
Given anticipated tax benefits of approximately $40 million from the transaction, the net purchase price is approximately $1.32 billion, representing approximately a 6.3x multiple of LTM EBITDA, excluding synergies.
鑑於該交易預計將帶來約4000萬美元的稅收優惠，淨收購價約爲13.2億美元，約爲LtM EBITDA的6.3倍，不包括協同效應。
Rotech provides home medical equipment in the U.S. The company has over 4,200 employees and provides products and services in 46 states through approximately 325 operating locations.
Rotech 在美國提供家用醫療設備。該公司擁有 4,200 多名員工，通過大約 325 個運營地點在 46 個州提供產品和服務。
Rotech generated approximately $750 million of revenue and an EBITDA margin of nearly 30% in 2023.
Rotech在2023年創造了約7.5億美元的收入和近30％的息稅折舊攤銷前利潤率。
The deal strengthens Owen & Minor's Patient Direct product offerings through expansion across a complementary portfolio and accelerates the growth path for the Patient Direct segment as outlined at the December 2023 Investor Day to achieve $5 billion in revenue by 2028.
該協議通過擴展互補產品組合來加強Owen & Minor的Patient Direct產品供應，並加快了Patient Direct細分市場的增長道路，如2023年12月投資者日所述，到2028年實現50億美元的收入。
The transaction provides a significant synergy opportunity of approximately $50 million by the end of year three, with further upside potential and prospects for additional revenue synergies in the near and long term.
到第三年年底，該交易提供了約5000萬美元的重大協同機會，具有進一步的上行潛力，並有望在短期和長期內實現額外的收入協同效應。
Owens & Minor also announced selected preliminary financial results for the second quarter of 2024, with revenue of $2.65 billion—$2.67 billion versus a consensus of $2.64 billion.
歐文斯和米諾還公佈了2024年第二季度的部分初步財務業績，收入爲26.5億美元至26.7億美元，而市場預期爲26.4億美元。
The healthcare logistics services company sees adjusted EPS of $0.32 – $0.36 compared to a consensus of $0.31.
這家醫療保健物流服務公司預計調整後的每股收益爲0.32美元至0.36美元，而市場普遍預期爲0.31美元。
In the second quarter of 2024, the company incurred a one-time income tax charge of $17 million ($0.22 per share) due to a recent decision on Notices of Proposed Adjustments from 2020 and 2021, communicated in late June 2024. A related cash payment of $30-$35 million is expected in the second half of 2024. The company anticipates resolving the matter without further financial impact.
由於最近於2024年6月下旬發佈的關於2020年和2021年擬議調整通知的決定，該公司在2024年第二季度產生了1,700萬美元（每股0.22美元）的一次性所得稅費用。預計將在2024年下半年支付3000萬至3500萬美元的相關現金。該公司預計將在不產生進一步財務影響的情況下解決此事。
For 2024, Owens & Minor reaffirmed its revenue outlook of $10.5 billion-$10.9 billion compared to a consensus of $10.66 billion.
歐文斯和米諾重申其2024年的收入前景爲105億至109億美元，而市場普遍預期爲106.6億美元。
The company continues to see 2024 adjusted EPS of $1.40-$1.70 versus the consensus of $1.53.
該公司繼續預計，2024年調整後的每股收益爲1.40美元至1.70美元，而市場普遍預期爲1.53美元。
Price Action: OMI stock is up 7.38% at $16.44 at last check Tuesday.
價格走勢：在週二的最後一次檢查中，OMI股價上漲7.38％，至16.44美元。
Photo via Shutterstock
照片來自 Shutterstock
- Cancer-Focused Cellectar Biosciences Stock Trades Lower Despite Meeting Goal In Blood Cancer Study.
- 儘管血液癌研究達到了目標，但以癌症爲重點的Celectar Biosciences股票的交易價格仍走低。